Mainz Biomed B.V.
MYNZ · NASDAQ
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $287 | $373 | $521 | $215 |
| % Growth | -23.2% | -28.3% | 142.5% | – |
| Cost of Goods Sold | $597 | $117 | $202 | $163 |
| Gross Profit | -$310 | $256 | $319 | $40 |
| % Margin | -108.2% | 68.6% | 61.3% | 18.7% |
| R&D Expenses | $2,768 | $2,596 | $3,243 | $3,854 |
| G&A Expenses | $2,877 | $3,557 | $4,523 | $3,531 |
| SG&A Expenses | $5,013 | $5,891 | $6,884 | $8,599 |
| Sales & Mktg Exp. | $2,349 | $2,334 | $2,361 | $1,248 |
| Other Operating Expenses | $0 | $656 | $0 | $1,448 |
| Operating Expenses | $7,781 | $9,144 | $10,126 | $13,901 |
| Operating Income | -$8,091 | -$8,888 | -$9,807 | -$12,231 |
| % Margin | -2,822.1% | -2,381.5% | -1,883.2% | -5,695.2% |
| Other Income/Exp. Net | -$253 | -$1,739 | -$1,216 | $748 |
| Pre-Tax Income | -$8,344 | -$10,627 | -$11,024 | -$5,183 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8,344 | -$10,627 | -$11,024 | -$5,183 |
| % Margin | -2,910.3% | -2,847.4% | -2,116.8% | -2,413.5% |
| EPS | -2.65 | -7.71 | -19.73 | -11.73 |
| % Growth | 65.6% | 60.9% | -68.2% | – |
| EPS Diluted | -2.65 | -7.71 | -19.73 | -11.73 |
| Weighted Avg Shares Out | 3,144 | 968 | 559 | 442 |
| Weighted Avg Shares Out Dil | 3,144 | 968 | 559 | 442 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $215 | $1,075 | $659 | $663 |
| Depreciation & Amortization | $348 | $681 | $336 | $460 |
| EBITDA | -$7,743 | -$10,087 | -$9,471 | -$12,611 |
| % Margin | -2,700.7% | -2,702.8% | -1,818.7% | -5,872% |